First vitiligo patient enrolled in afamelanotide monotherapy study
CUV104 study to evaluate the role of afamelanotide as monotherapy in patients...
Read More
CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients
European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...
Read More
PRÉNUMBRA® for stroke
Melbourne, Australia, 28 July 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
CLINUVEL progresses vitiligo treatment program
A new potential therapy for the pigment loss disorder vitiligo will undergo...
Read More
Positive final results in stroke
CLINUVEL today released positive final results of the open label pilot study...
Read More
CLINUVEL Extends Employment Agreement With CEO
CLINUVEL today announced that it has extended the Employment Agreement with the...
Read More
DNA Repair Communiqué II
In this DNA Repair Communiqué II we delve deeper into the topic...
Read More
First XP-V Patient Treated in CLINUVEL DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read More
Afamelanotide in stroke (AIS) – positive preliminary results
CLINUVEL today released positive preliminary results from its pilot study (CUV801) in...
Read More
DNA Repair Communiqué I
This first Communiqué in a series on DNA forms an introductory foundation,...
Read More
CLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read More
SCENESSE® continued in Germany
CLINUVEL today announced that it has entered a second agreement with the...
Read More
CLINUVEL completes enrolment in world-first stroke study
CLINUVEL today announced that it has completed enrolment in its world-first study...
Read More
Vitiligo Communiqué IV
CLINUVEL’s fourth Vitiligo Communiqué discusses the long-term consequences, both physical and psychological,...
Read More
First Patient Treated in CLINUVEL DNA Repair Study
Melbourne, Australia, 22 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More